Recursion Pharmaceuticals (RXRX) Income from Non-Controlling Interests (2020 - 2021)
Recursion Pharmaceuticals (RXRX) reported Income from Non-Controlling Interests of $43.4 million for Q2 2021, up 129.11% on a YoY basis from $18.9 million in Q2 2020, and up 241.29% quarter-over-quarter from -$30.7 million in Q1 2021.
Recursion Pharmaceuticals (RXRX) Income from Non-Controlling Interests (2020 - 2021) Analysis & Trends
Recursion Pharmaceuticals has reported Income from Non-Controlling Interests for 2 years, with the latest figure at $43.4 million in Q2 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -13.75 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Recursion Pharmaceuticals | 1.71 Bn | 1.05 Bn | -6.02 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2021 | 43.40 Mn |
| Mar 31, 2021 | -30.72 Mn |
| Jun 30, 2020 | 18.94 Mn |
| Mar 31, 2020 | -18.42 Mn |